Gemmer Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Gemmer Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-110	Closed	-$9K	–	1162
2022 Q1	$9K	Buy	110 +35	+47%	+$3.23K	﹤0.01%	762
2021 Q4	$8K	Buy	+75	New	+$9.05K	﹤0.01%	847
2017 Q1	–	Sell	-200	Closed	-$12K	–	1251
2016 Q4	$12K	Buy	+200	New	+$12.3K	0.01%	547
2014 Q3	–	Sell	-75	Closed	-$4K	–	1480
2014 Q2	$4K	Hold	75	–	–	﹤0.01%	1011
2014 Q1	$4K	Buy	+75	New	+$3.84K	﹤0.01%	991

Other funds holding XBI

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Gemmer Asset Management's XBI Position: Q2 2022 in Review

Gemmer Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2022, closing a stake of 110 shares — an estimated $9K sold.

Gemmer Asset Management first reported a position in XBI in Q1 2014 and held it in 5 quarters. The position peaked at $12K in Q4 2016. 704 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Gemmer Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2022 after selling out during the quarter.
Gemmer Asset Management sold 110 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $9K.
Gemmer Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2014 and held it in 5 quarters.
Gemmer Asset Management's State Street SPDR S&P Biotech ETF position peaked at $12K in Q4 2016.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Gemmer Asset Management's 13F filing for Q2 2022, filed 22 Jul 2022.